首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Oncoimmunology

缩写:ONCOIMMUNOLOGY

ISSN:2162-402X

e-ISSN:2162-402X

IF/分区:6.3/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引892
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Mirte van der Heijden,James Hugo Armstrong Clubb,Pande Putu Erawijantari et al. Mirte van der Heijden et al.
Accumulating evidence implicates the microbiome as an important determinant of clinical outcomes in cancer therapies; however, the role of the microbiome in oncolytic virus therapy remains largely unexplored. We investigated the gut microbi...
Liwei Zhao,Oliver Kepp,Guido Kroemer et al. Liwei Zhao et al.
Aging impairs vaccine responses. Dai et al. reported that defective cDC2 migration in immunized old mice, diminishing humoral and cellular immunity. Oral yeast-derived nanoparticles restore DC migration and vaccine efficacy. These findings ...
Stefanie Höppner,Lisa Werr,Beata Szilagyi et al. Stefanie Höppner et al.
Telomerase is active in the majority of high-risk neuroblastomas, a pediatric tumor associated with poor patient outcomes. In other cancer types, resistance to immune checkpoint blockade was overcome by induction of telomere dysfunction usi...
Anna Tiefenthaller,Nikko Brix,Roman Hennel et al. Anna Tiefenthaller et al.
The local immune effects of cancer radiotherapy remain poorly characterized in humans due to limited access to irradiated tissue. Mechanistic insights largely derive from preclinical models employing tumor-intact, neoadjuvant-like settings....
Jesper van Eck van der Sluijs,Anne H C Valk,Eline J H van Houtum et al. Jesper van Eck van der Sluijs et al.
The glyco-immune checkpoints Siglec-7 and Siglec-9 have received considerable interest as targets for cancer immunotherapy. How Siglec-7/9-sialic acid cis-interactions on immune cells influence trans-signaling induced by tumor cells and whe...
Juan Luis Onieva,Elisabeth Pérez-Ruiz,Ville Vilkki et al. Juan Luis Onieva et al.
The emergence of immune checkpoint inhibitors (ICIs) has transformed the treatment landscape of metastatic melanoma. However, despite its success, reliable biomarkers for predicting primary resistance are not available in clinical practice....
Elise Arlt,Nadine Bley,Alexander Rausch et al. Elise Arlt et al.
Pancreatic ductal adenocarcinoma (PDAC) ranks among the most aggressive malignancies and exhibits a higher prevalence and poorer prognosis in male patients. While both the importance of natural killer (NK) cells in anti-tumor immunity and s...
Adrian Georg Simon,Bastian Grothey,Su Ir Lyu et al. Adrian Georg Simon et al.
The tumor immune microenvironment (TIME) influences tumor biology and therapeutic response, yet its composition and clinical relevance in angiosarcoma, an ultrarare and aggressive sarcoma with a dismal prognosis, remain poorly defined. To a...
Belén Aparicio,Leyre Silva,Marta Ruiz et al. Belén Aparicio et al.
In some cancers, patients responding to immune checkpoint inhibitors (ICI) usually harbor tumors with a higher tumor mutational burden and increased lymphocyte infiltration targeting mutation-derived neoantigens (neoAgs). In the NASIR-HCC t...